Mostrar el registro sencillo del ítem

dc.contributorConsorcio Tecnologico en Biomedicinaclinico-molecular S. A.es_ES
dc.contributor.advisorMauricio Bulnes Bulnes Carrascoes_ES
dc.date2011-08-25es_ES
dc.date.accessioned2011-12-05T20:31:02Z
dc.date.available2018-06-12T08:15:11Z
dc.date.issued2011-12-05
dc.identifier2011-11133-INNOVA_PRODUCCIONes_ES
dc.identifier2011-11133es_ES
dc.identifier.urihttp://repositoriodigital.corfo.cl/handle/11373/2811
dc.descriptionTo transfer the results of the project oral live vaccine against helicobacter pylori to global markets.es_ES
dc.description.abstractThe infection by helicobacter pylori causes several diseases with different severity from a simple gastritis and going through chronic gastritis ulcer gastric atrophy MALT lymphoma and gastric carcinoma. Gastric cancer has been recognized as the 2nd most fatal form of cancer in the world. Of particular relevance there is a causative relationship between H. pylori and gastric cancer and a H. pylori vaccine would fill an urgent medical need. We are developing 2 prototypes of oral vaccines: one is based on the use of an attenuated bacterium and the other a safe probiotic both as live carriers of helicobacter pylori antigens to stimulate the immune system. It is well known that safety is a very important issue for drugs and in particular for vaccines. In this context probiotics are safer than attenuated bacterial strains. In addition attenuated strains present more side effects after vaccination. However attenuated strains induce a stronger response than probiotics so they could be more appropriate as live vaccines. Therefore we are currently working on both options so the best solution combining safety and efficacy will be chosen. The approach of using oral live vaccines has strong support. Firstly oral administration induces a general mucosal response at the gastrointestinal epithelia which is absent or reduced when intramuscular or subcutaneous via are used. Secondly oral administration is more acceptable to users rather than injections particularly when children need to be vaccinated. Finally in general injected substances such as medicines and vaccines compared to those orally given need a more strict manufacturing control because of toxicity and bacterial contamination and makes vaccine preparation a more expensive procedure. We have selected few particular antigens which are conserved in amino acid sequence and have wide distribution among H. pylori strains in order to assure a wide coverage of protection therefore our vaccines should be effective in a wider population. The oral live vaccine aims to offer a friendly presentation for users and should be safer than vaccines that directly uses the attenuated disease agent as a package of antigens to induce the immune system. In addition vaccines are usually prophylactic but in some cases they may be also therapeutic. At present we cannot anticipate if our product will present therapeutic properties but this aspect should be answered after some animal essays. If this feature is present in our prototypes it will add a higher value to these products.es_ES
dc.description.sponsorshipCorporación de Fomento de la Producciónes_ES
dc.subjectBioquímicaes_ES
dc.subjectVacunases_ES
dc.subjectProducción de vacunases_ES
dc.titleDevelopment of Oral Live Vaccine Prototypes Against Helicobacter Pylori Infectionses_ES
dc.typePproyectoes_ES
cf.beneficiario.actividadeconomicaActividades de investigaciónes_ES
cf.beneficiario.razonsocialConsorcio Tecnologico en Biomedicinaclinico-molecular S. A.es_ES
cf.beneficiario.rut76011738-2es_ES
cf.beneficiario.tamanoempresaMicro Empresaes_ES
cf.beneficiario.tipoparticipanteBeneficiarioes_ES
cf.beneficiario.tipopersonaJurídicaes_ES
cf.comite.fecha2011-09-22es_ES
cf.comite.nombreComité innovaes_ES
cf.costo.beneficiarioaprobado0es_ES
cf.costo.corfoaprobado0es_ES
cf.costo.corforeal16750000es_ES
cf.costo.tipomonedaPeso chilenoes_ES
cf.ejecutivo.nombreMauricio Bulnes Bulnes Carrascoes_ES
cf.ejecutivo.rut125144586es_ES
cf.fecha.inicio2011-08-25es_ES
cf.fecha.postulacion2011es_ES
cf.proyecto.clusterMedicina y salud humanaes_ES
cf.proyecto.estadoTerminadoes_ES
cf.proyecto.instrumentoGo To Market - De la Idea al Mercadoes_ES
cf.proyecto.tipopostulacionIndividuales_ES
cf.proyecto.unidadorigenInnovaes_ES
cf.region.postulacionRM Santiagoes_ES
cf.region.ejecucionRM Santiagoes_ES
cf.region.impactoRM Santiagoes_ES
cf.costo.beneficiarioreal7416668es_ES
cf.sistemaorigenBDCes_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem